Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8718598 | 0.79 | MAPT (0.50) | GAANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL28527555 | 0.79 | MEN1 (0.50) | GAANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL20335404 | 0.79 | MEN1 (0.50) | GAANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL13188669 | 0.79 | GAA (0.51) | GAANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL14438098 | 0.79 | MAPT (0.50) | GAANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL8718594 | 0.79 | MAPT (0.50) | GAANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL1002645 | 0.79 | NOX1 (0.34) | GAANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL8221412 | 0.79 | NOX1 (0.34) | GAANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL1002644 | 0.79 | NOX1 (0.34) | GAANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL19918085 | 0.79 | MEN1 (0.50) | GAANPC1RAB9AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842576-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| EP-2842576-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| EP-2033662-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| EP-1708755-B1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| EP-2368579-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010102673-A1 | HELLEBRIN AND HELLEBRIGENIN DERIVATIVES | UNIBIOSCREEN S.A. (BE) | 2010-09-16 | — | — | WO | disclosed |
| US-20100009917-A1 | Modulating Enzymatic Processes by Addition of Diolcontaining Substances | NOVO NORDISK HEALTH CARE AG (CH) | 2010-01-14 | — | — | US | disclosed |
| US-20100009917-A1 | Modulating Enzymatic Processes by Addition of Diolcontaining Substances | NOVO NORDISK HEALTH CARE AG (CH) | 2010-01-14 | — | — | US | disclosed |
| US-7524813-B2 | Selectively conjugated peptides and methods of making the same | NOVO NORDISK HEALTH CARE AG (CH) | 2009-04-28 | — | — | US | disclosed |
| US-7524813-B2 | Selectively conjugated peptides and methods of making the same | NOVO NORDISK HEALTH CARE AG (CH) | 2009-04-28 | — | — | US | disclosed |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-2033662-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| WO-2008101957-A1 | MODULATING ENZYMATIC PROCESSES BY ADDITION OF DIOLCONTAINING SUBSTANCES | NOVO NORDISK HEALTH CARE AG (DK) | 2008-08-28 | — | — | WO | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009917-A1 | Modulating Enzymatic Processes by Addition of Diolcontaining Substances | HSD17B14, CES2, PNLIP | GAA 8/4885NPC1 2475/4885RAB9A 4513/4885 |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | TGM2, TGM3, TGM1 | GAA 78/4885NPC1 4732/4885RAB9A 1825/4885 |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | GHRHR, GHITM, HDGF | GAA 510/4885NPC1 2911/4885RAB9A 3608/4885 |
| US-20070111926-A1 | Conjugation of peptides | DNPEP, ENPEP, ANPEP | GAA 426/4885NPC1 3576/4885RAB9A 3236/4885 |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | TGM2, TGM3, TGM1 | GAA 78/4885NPC1 4732/4885RAB9A 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.